Urokinase receptor: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
← Older editNewer edit →
Michal Harel (talk | contribs)
31,761 edits
No edit summary
Michal Harel (talk | contribs)
31,761 edits
No edit summary
Line 11: Line 11:
== Relevance ==
== Relevance ==


Elevated levels of soluble uPAR are associated with kidney disease<ref>PMID:26539835</ref>.  uPAR which is expressed at high levels in malignant tutors is unattractive target for treatment of cancer<ref>PMID:35303878</ref>.  uPAR activity in cancer cells may counteract the activity of anticancer drugs<ref>PMID:26283964</ref>.
Elevated levels of soluble uPAR are associated with kidney disease<ref>PMID:26539835</ref>.  uPAR which is expressed at high levels in malignant tutors is an attractive target for treatment of cancer<ref>PMID:35303878</ref>.  uPAR activity in cancer cells may counteract the activity of anticancer drugs<ref>PMID:26283964</ref>.


==Structural highlights==
==Structural highlights==

Revision as of 10:05, 10 April 2024


Function

Urokinase receptor or Urokinase plasminogen activator surface receptor or CD87 (uPAR) plays an important role in migration of T cells[1]. uPAR is a GPI-anchored membrane protein. It triggers cell signalling and regulates gene expression within the cell

Disease

uPAR can control the shift between tumor dormancy and proliferation to form metastasis[2]

Relevance

Elevated levels of soluble uPAR are associated with kidney disease[3]. uPAR which is expressed at high levels in malignant tutors is an attractive target for treatment of cancer[4]. uPAR activity in cancer cells may counteract the activity of anticancer drugs[5].

Structural highlights

3D structures of urokinase receptor

Urokinase plasminogen activator surface receptor 3D structures

References

  1. ↑ Nykjaer A, Møller B, Todd RF 3rd, Christensen T, Andreasen PA, Gliemann J, Petersen CM. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol. 1994 Jan 15;152(2):505-16 PMID:8283034
  2. ↑ Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, Zambrano N, Fontanini G, Servadio A, Pignataro G, Grumetto L, Lavecchia A, Bruzzese D, Iaccarino A, Troncone G, Veneziani BM, Montuori N, Placido S, Bianco R. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci Rep. 2017 Aug 24;7(1):9388. PMID:28839232 doi:10.1038/s41598-017-10062-1
  3. ↑ Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med. 2015 Nov 12;373(20):1916-25. PMID:26539835 doi:10.1056/NEJMoa1506362
  4. ↑ Zhai BT, Tian H, Sun J, Zou JB, Zhang XF, Cheng JX, Shi YJ, Fan Y, Guo DY. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J Transl Med. 2022 Mar 18;20(1):135. PMID:35303878 doi:10.1186/s12967-022-03329-3
  5. ↑ Gonias SL, Hu J. Urokinase receptor and resistance to targeted anticancer agents. Front Pharmacol. 2015 Jul 27;6:154. PMID:26283964 doi:10.3389/fphar.2015.00154

Human uPAR (grey) complex with glycosylated uPA (magenta) and sulfate (PDB code 2i9b)

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=Urokinase_receptor&oldid=4124121"